Sun enjoys fleeting profit boost from oxaliplatin

Talk about a rollercoaster: Sun Pharma profits tripled in the first quarter, driven by one-time U.S. sales of chemotherapy drug oxaliplatin. But, alas, the generics maker stopped manufacturing the drug at the end of June, to avoid infringing the Sanofi Aventis patent. Sun has filed suit against Sanofi in the U.S. and says it will begin making the drug again in the event of a positive court ruling. Article

Suggested Articles

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot. 

The FDA recently asked five drug manufacturers to recall the commonly used diabetes med metformin. With COVID-19 raging, is metformin just the start?

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.